Preclinical efficacy of MEK inhibition in Nras-mutant AML

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

(2014) A. N. Hata et al.   CANCER RESEARCH

Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia

(2014) Monique Dail et al.   NATURE

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

(2014) Liran I. Shlush et al.   NATURE

The clinical development of MEK inhibitors

(2014) Yujie Zhao et al.   Nature Reviews Clinical Oncology

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

(2014) M. R. Corces-Zimmerman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies

(2014) O. Abdel-Wahab et al.   Cancer Discovery

NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions

(2013) J. Wang et al.   BLOOD

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

(2013) N. Jain et al.   CLINICAL CANCER RESEARCH

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

(2013) Gunther Zimmermann et al.   NATURE

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras-Driven Hematopoietic Transformation

(2013) J. Xu et al.   Cancer Discovery

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

(2012) Ryan B. Corcoran et al.   CANCER CELL

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

(2012) John S. Welch et al.   CELL

RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group

(2012) Hirozumi Sano et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice

(2012) Tiffany Chang et al.   JOURNAL OF CLINICAL INVESTIGATION

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia

(2012) M. Jan et al.   Science Translational Medicine

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype

(2011) F. Damm et al.   BLOOD

Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras

(2011) J. Xu et al.   BLOOD

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212

(2011) J. Jing et al.   MOLECULAR CANCER THERAPEUTICS

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus

(2010) Q. Li et al.   BLOOD

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

(2010) C. Bachas et al.   BLOOD

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Small-molecule inhibition of APT1 affects Ras localization and signaling

(2010) Frank J Dekker et al.   Nature Chemical Biology

Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents

(2010) M. Dail et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras

(2009) Jennifer O. Lauchle et al.   NATURE

Targeting Ras in Myeloid Leukemias

(2008) B. S. Braun et al.   CLINICAL CANCER RESEARCH

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE